![]() |
|||
|
|
|
|
| UPDATE: May 2009 | MW: 232.26 | MF: C12H12N2O3 |
SYNONYMS:
|
|
| |
SKIN AND EYE IRRITATION DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
N/R |
N/R
|
N/R
|
N/R
|
| |||
MUTATION DATA AND REFERENCES:
SYSTEM TEST
|
ROUTE/ | ORGANISM/ TISSUE
DOSE
|
REFERENCE
|
cytogenetic analysis
|
hamster
ovary
|
15 mmol/L
|
PMRSDJ 5,433,1985
|
cytogenetic analysis
|
hamster
lung
|
2 gm/L/48 hour
|
GMCRDC 27,95,1981
|
cytogenetic analysis
|
hamster
liver
|
100 mg/L
|
PMRSDJ 5,397,1985
|
cytogenetic analysis
|
human
leukocyte
|
400 mg/L/90 minute
|
CHDDAT 268,191,1969
|
cytogenetic analysis
|
human
lymphocyte
|
10 mg/L
|
MUREAV 204,623,1988
|
cytogenetic analysis
|
oral | mouse
3,332 µg/kg
|
IJEBA6 22,666,1984
|
cytogenetic analysis
|
oral | mouse
45 mg/kg/30 day- intermittent
|
FCTOD7 46,1474,2008
|
dominant lethal test
|
oral | mouse
210 mg/kg/5 day- continuous
|
FCTOD7 21,335,1983
|
DNA adduct
|
oral | mouse
600 mg/kg/10 day- continuous
|
TXAPA9 226,338,2008
|
DNA damage
|
human
other cell types
|
1 mmol/L/3 hour (+enzymatic activation step)
|
MUTAEX 16,439,2001
|
DNA damage
|
rat
liver
|
1 mmol/L
|
MUREAV 368,59,1996
|
DNA inhibition
|
rat
liver
|
1,500 µmol/L
|
JCROD7 116,259,1990
|
unscheduled DNA synthesis
|
oral | mouse
400 mg/kg/4 day- continuous
|
CALEDQ 48,43,1989
|
unscheduled DNA synthesis
|
oral | rat
4,410 mg/kg/21 week- continuous
|
CALEDQ 33,119,1986
|
unscheduled DNA synthesis
|
rat
liver
|
100 pmol/L
|
CRNGDP 6,811,1985
|
mutation in microorganisms
|
mouse
lymphocyte
|
2 gm/L (+enzymatic activation step)
|
PMRSDJ 5,587,1985
|
mutation in microorganisms
|
Salmonella typhimurium
|
100 µg/plate (+enzymatic activation step)
|
MUREAV 147,255,1985
|
mutation in microorganisms
|
Salmonella typhimurium
|
500 µg/plate (-enzymatic activation step)
|
PMRSDJ 5,187,1985
|
mutation in microorganisms
|
Salmonella typhimurium
|
2,800 mg/L/2 hour (-enzymatic activation step)
|
MUREAV 578,210,2005
|
mutation in microorganisms
|
Salmonella typhimurium
|
1,500 mg/L/2 hour (+enzymatic activation step)
|
MUREAV 578,210,2005
|
mutation in microorganisms
|
Saccharomyes cerevisiae
|
500 mg/L (+/-enzymatic activation step)
|
PMRSDJ 5,271,1985
|
micronucleus test
|
oral | mouse
18 mg/kg
|
MUREAV 563,1,2004
|
micronucleus test
|
oral | mouse
22.5 mg/kg/15 day- intermittent
|
FCTOD7 46,1474,2008
|
gene conversion and mitotic recombination
|
Saccharomyes cerevisiae
|
500 mg/L
|
PMRSDJ 5,271,1985
|
mutation in mammalian somatic cells
|
human
lymphocyte
|
1 gm/L
|
PMRSDJ 5,497,1985
|
mutation in mammalian somatic cells
|
mouse
lymphocyte
|
500 mg/L
|
PMRSDJ 5,587,1985
|
morphological transform
|
hamster
embryo
|
100 mg/L
|
PMRSDJ 5,665,1985
|
morphological transform
|
hamster
embryo
|
10 mg/L/6 day
|
MUREAV 572,45,2005
|
morphological transform
|
mouse
embryo
|
667 mg/L
|
PMRSDJ 5,639,1985
|
morphological transform
|
oral | rat
1,260 mg/kg/6 week
|
CRNGDP 9,387,1988
|
other mutation test systems
|
mouse
liver
|
3 mmol/L
|
MUREAV 448,193,2000
|
other mutation test systems
|
Salmonella typhimurium
|
1 gm/L
|
MUREAV 192,239,1987
|
phage inhibition capacity
|
intraperitoneal | rat
240 mg/kg/3 day- intermittent
|
HPTLD9 8,1051,1988
|
sister chromatid exchange
|
hamster
ovary
|
15 mmol/L
|
PMRSDJ 5,433,1985
|
sister chromatid exchange
|
hamster
lung
|
10 mg/L
|
BJCAAI 45,769,1982
|
sex chromosome loss and nondisjunction
|
oral | Drosophila melanogaster
2 mg/6 day
|
SOGEBZ 11,718,1975
|
sex chromosome loss and nondisjunction
|
Saccharomyes cerevisiae
|
430 µmol/L
|
MUREAV 144,67,1985
|
specific locus test
|
oral | mouse
54,000 mg/kg/180 day- continuous
|
BCPCA6 62,685,2001
|
specific locus test
|
oral | rat
49,350 mg/kg/47 week- continuous
|
CALEDQ 135,215,1999
|
sperm morphology
|
oral | mouse
72 mg/kg
|
MUREAV 563,1,2004
|
sperm morphology
|
oral | mouse
90 mg/kg/60 day- intermittent
|
FCTOD7 46,1474,2008
|
| |||
REPRODUCTIVE EFFECTS DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
intramuscular | rat
lowest published toxic dose: 200 mg/kg (18-20 day pregnant/15 day after birth)
|
Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material) | Reproductive: Specific developmental abnormalities: Central nervous system
TJADAB 26,21,1982
|
intramuscular | rabbit
lowest published toxic dose: 175 gm/kg (20-27 day pregnant)
|
Reproductive: Effects on newborn: Biochemical and metabolic
|
AJOGAH 124,529,1976
|
intraperitoneal | hamster
lowest published toxic dose: 140 mg/kg (1 day prior to copulation)
|
Reproductive: Effects on fertility: Other measures of fertility
|
PSEBAA 162,170,1979
|
intraperitoneal | hamster
lowest published toxic dose: 560 mg/kg (9-15 day pregnant)
|
Reproductive: Specific developmental abnormalities: Hepatobiliary system
|
ABBIA4 134,76,1969
|
intraperitoneal | mouse
lowest published toxic dose: 150 mg/kg (8-10 day pregnant)
|
Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)
|
TJADAB 1,393,1968
|
intraperitoneal | mouse
lowest published toxic dose: 560 mg/kg (8-14 day pregnant)
|
Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)
|
ACATA5 58,217,1964
|
intraperitoneal | mouse
lowest published toxic dose: 300 mg/kg (17-19 day pregnant)
|
Reproductive: Effects on newborn: Biochemical and metabolic
|
AJANA2 138,449,1973
|
intraperitoneal | rat
lowest published toxic dose: 1 gm/kg (1-20 day pregnant)
|
Reproductive: Effects on embryo or fetus: Extra embryonic structures (e.g., placenta, umbilical cord) | Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Other developmental abnormalities
AJOGAH 107,1250,1970
|
intraperitoneal | rat
lowest published toxic dose: 180 mg/kg (19-21 day pregnant)
|
Reproductive: Other effects to embryo or fetus
|
TXAPA9 73,457,1984
|
multiple | rat
lowest published toxic dose: 340 mg/kg (20-22 day pregnant/7 day after birth)
|
Reproductive: Effects on newborn: Other postnatal measures or effects
|
AIPTAK 187,155,1970
|
oral | mouse
lowest published toxic dose: 210 mg/kg (5 day male)
|
Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)
FCTOD7 21,335,1983
|
oral | mouse
lowest published toxic dose: 400 mg/kg (6-15 day pregnant)
|
Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)
|
TXCYAC 6,323,1976
|
oral | mouse
lowest published toxic dose: 33 mg/kg (9-19 day pregnant)
|
Reproductive: Effects on newborn: Physical
|
IJMDAI 14,929,1978
|
oral | mouse
lowest published toxic dose: 3,600 mg/kg (9-18 day pregnant)
|
Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | Reproductive: Effects on newborn: Behavioral
PSCHDL 68,301,1980
|
oral | mouse
lowest published toxic dose: 1,080 mg/kg (16-18 day pregnant)
|
Reproductive: Specific developmental abnormalities: Central nervous system
|
ACATA5 108,370,1980
|
oral | mouse
lowest published toxic dose: 63 gm/kg (1-21 day pregnant)
|
Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material)
|
TJADAB 25(1),15A,1982
|
oral | mouse
lowest published toxic dose: 30 gm/kg (9-18 day pregnant)
|
Reproductive: Specific developmental abnormalities: Central nervous system
|
BRBUDU 46,203,1998
|
oral | mouse
lowest published toxic dose: 30 gm/kg (9-18 day pregnant)
|
Reproductive: Specific developmental abnormalities: Urogenital system | Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Behavioral
TJADAB 19,54A,1979
|
oral | mouse
lowest published toxic dose: 30 gm/kg (9-18 day pregnant)
|
Reproductive: Effects on newborn: Other postnatal measures or effects | Reproductive: Effects on newborn: Delayed effects
TJADAB 19,54A,1979
|
oral | rat
lowest published toxic dose: 880 mg/kg (7-17 day pregnant)
|
Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | Reproductive: Specific developmental abnormalities: Blood and lymphatic systems (including spleen and marrow)
SEIJBO 19,178,1979
|
oral | rat
lowest published toxic dose: 440 mg/kg (7-17 day pregnant)
|
Reproductive: Specific developmental abnormalities: Musculoskeletal system
|
TJADAB 20,157,1979
|
oral | rat
lowest published toxic dose: 300 mg/kg (4-8 day pregnant)
|
Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | Reproductive: Effects on fertility: Abortion
FESTAS 22,735,1971
|
oral | rat
lowest published toxic dose: 320 mg/kg (7-10 day pregnant)
|
Reproductive: Effects on newborn: Weaning or lactation index (e.g., # alive at weaning per # alive at day 4) | Reproductive: Effects on newborn: Behavioral
JPETAB 227,274,1983
|
oral | rat
lowest published toxic dose: 800 mg/kg (6-13 day pregnant)
|
Reproductive: Effects on embryo or fetus: Fetal death
|
TJADAB 24,1,1981
|
oral | rat
lowest published toxic dose: 280 mg/kg (1-7 day after birth)
|
Reproductive: Effects on newborn: Biochemical and metabolic
|
SCIEAS 211,719,1981
|
oral | rat
lowest published toxic dose: 60 mg/kg (7-18 day pregnant)
|
Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive)
|
JPETAB 227,274,1983
|
oral | rat
lowest published toxic dose: 810 mg/kg (1 day pregnant-5 day after birth)
|
Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | Reproductive: Effects on newborn: Behavioral
EKFAE9 56,36,1993
|
oral | rat
lowest published toxic dose: 300 mg/kg (multigenerations)
|
Reproductive: Specific developmental abnormalities: Respiratory system | Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain)
EKFAE9 56,38,1993
|
oral | rabbit
lowest published toxic dose: 450 mg/kg (8-16 day pregnant)
|
Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth)
TXAPA9 10,244,1967
|
oral | rabbit
lowest published toxic dose: 450 mg/kg (8-16 day pregnant)
|
Reproductive: Specific developmental abnormalities: Musculoskeletal system | Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system
TXAPA9 10,244,1967
|
oral | rabbit
lowest published toxic dose: 536 mg/kg (3-31 day pregnant)
|
Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material) | Reproductive: Effects on newborn: Biochemical and metabolic
FOMOAJ 38,259,1979
|
oral | woman
lowest published toxic dose: 151 mg/kg (27-39 week pregnant)
|
Reproductive: Specific developmental abnormalities: Musculoskeletal system | Reproductive: Effects on newborn: Drug dependence
JOPDAB 80,190,1972
|
oral | woman
lowest published toxic dose: 3,600 µg/kg (26 week pregnant)
|
Reproductive: Specific developmental abnormalities: Hepatobiliary system | Reproductive: Effects on newborn: Biochemical and metabolic
AJOGAH 159,1491,1988
|
parenteral | mouse
lowest published toxic dose: 60 µg/kg (1 day prior to copulation)
|
Reproductive: Maternal effects: Uterus, cervix, vagina
|
PPHAD4 5,157,1985
|
subcutaneous | mouse
lowest published toxic dose: 280 mg/kg (15-21 day pregnant)
|
Reproductive: Effects on newborn: Behavioral
|
DEPBA5 8,305,1975
|
subcutaneous | rat
lowest published toxic dose: 320 mg/kg (multigenerations)
|
Reproductive: Effects on fertility: Male fertility index (e.g., # males impregnating females per # males exposed to fertile nonpregnant females)
|
PPHAD4 1,55,1980
|
subcutaneous | rat
lowest published toxic dose: 750 mg/kg (1 day prior to copulation)
|
Reproductive: Effects on fertility: Other measures of fertility
|
PSEBAA 139,741,1972
|
subcutaneous | rat
lowest published toxic dose: 20 mg/kg (5-8 day pregnant)
|
Reproductive: Effects on newborn: Behavioral
|
TJEMAO 89,265,1966
|
subcutaneous | rat
lowest published toxic dose: 320 mg/kg (12-19 day pregnant)
|
Reproductive: Specific developmental abnormalities: Urogenital system | Reproductive: Effects on newborn: Physical Reproductive: Effects on newborn: Delayed effects
EXMDA4 (551),250,1981
|
subcutaneous | rat
lowest published toxic dose: 160 mg/kg (17-20 day pregnant)
|
Reproductive: Effects on newborn: Physical | Reproductive: Effects on newborn: Delayed effects
PPHAD4 2,85,1982
|
unreported route | mouse
lowest published toxic dose: 40 mg/kg (1 day prior to copulation)
|
Reproductive: Effects on fertility: Other measures of fertility
|
FESTAS 12,346,1961
|
unreported route | rat
lowest published toxic dose: 40 mg/kg (17 day pregnant)
|
Reproductive: Effects on newborn: Other postnatal measures or effects
|
SCIEAS 216,640,1982
|
unreported route | woman
lowest published toxic dose: 491 mg/kg (1-39 week pregnant)
|
Reproductive: Specific developmental abnormalities: Body wall | Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Respiratory system
LANCAO 2,839,1972
|
unreported route | woman
lowest published toxic dose: 907 mg/kg (1-36 week pregnant)
|
Reproductive: Specific developmental abnormalities: Central nervous system | Reproductive: Specific developmental abnormalities: Urogenital system Reproductive: Effects on newborn: Other postnatal measures or effects
LANCAO 2,839,1972
|
unreported route | woman
lowest published toxic dose: 529 mg/kg (1-42 week pregnant)
|
Reproductive: Specific developmental abnormalities: Gastrointestinal system
|
LANCAO 2,839,1972
|
unreported route | woman
lowest published toxic dose: 454 mg/kg (1-36 week pregnant)
|
Reproductive: Specific developmental abnormalities: Central nervous system
|
LANCAO 2,839,1972
|
| |||
TUMORIGENIC DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
oral | mouse
lowest published toxic dose: 22 gm/kg/1 year- continuous
|
Tumorigenic: Neoplastic by RTECS criteria | Liver: Tumors
JNCIAM 51,1349,1973
|
oral | mouse
toxic dose : 38 gm/kg/90 week- continuous
|
Tumorigenic: Neoplastic by RTECS criteria | Lung, Thorax, or Respiration: Tumors Liver: Tumors
FCTXAV 11,433,1973
|
oral | mouse
toxic dose : 5,200 mg/kg/52 week- continuous
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Liver: Tumors
53HJAC -,145,1984
|
oral | mouse
lowest published toxic dose: 3,150 mg/kg/15 week- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Tumorigenic: Facilitates action of known carcinogens Liver: Tumors
CALEDQ 157,87,2000
|
oral | mouse
lowest published toxic dose: 44,800 mg/kg/25 week- continuous
|
Tumorigenic: Carcinogenic by RTECS criteria | Tumorigenic: Facilitates action of known carcinogens Liver: Tumors
CALEDQ 147,11,1999
|
oral | mouse
lowest published toxic dose: 319,200 mg/kg/114 week- continuous
|
Tumorigenic: Carcinogenic by RTECS criteria | Liver: Tumors
VOONC* 37,297,1991
|
oral | mouse
lowest published toxic dose: 14,700 mg/kg/35 week- continuous
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Tumorigenic: Facilitates action of known carcinogens Liver: Tumors
NSAPCC 375(Suppl 1),87,2007
|
oral | mouse
lowest published toxic dose: 14,700 mg/kg/35 week- continuous
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Tumorigenic: Facilitates action of known carcinogens Liver: Tumors
NSAPCC 375(Suppl 1),87,2007
|
oral | rat
lowest published toxic dose: 7,560 mg/kg/36 week- continuous
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Liver: Tumors Tumorigenic: Cells (cultured) transformed
GANNA2 69,679,1978
|
oral | rat
toxic dose : 4,200 mg/kg/20 week- continuous
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Liver: Tumors Tumorigenic: Cells (cultured) transformed
CALEDQ 5,139,1978
|
oral | rat
toxic dose : 30 mg/kg/78 week- continuous
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Liver: Tumors Endocrine: Thyroid tumors
CRNGDP 10,183,1989
|
oral | rat
toxic dose : 3,990 mg/kg/19 week- continuous
|
Tumorigenic: Carcinogenic by RTECS criteria | Endocrine: Thyroid tumors Tumorigenic: Cells (cultured) transformed
CRNGDP 4,935,1983
|
oral | rat
toxic dose : 2,520 mg/kg/12 week- continuous
|
Tumorigenic: Neoplastic by RTECS criteria | Endocrine: Thyroid tumors Tumorigenic: Cells (cultured) transformed
CRNGDP 4,935,1983
|
oral | rat
toxic dose : 2,100 mg/kg/12 week- continuous
|
Tumorigenic: Carcinogenic by RTECS criteria | Endocrine: Thyroid tumors Tumorigenic: Cells (cultured) transformed
IGAYAY 123,1069,1982
|
oral | rat
lowest published toxic dose: 1,260 mg/kg/6 week- continuous
|
Tumorigenic: Neoplastic by RTECS criteria | Liver: Tumors Tumorigenic: Facilitates action of known carcinogens
CALEDQ 141,211,1999
|
| |||
ACUTE TOXICITY DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
intracerebral | rat
lowest published toxic dose: 20 µg/kg
|
Peripheral Nerve and Sensation: Sensory change involving segmental distribution
|
BJMRDK 34,397,2001
|
inhalation | rat
lethal concentration : >4,100 µg/m3/4 hour
|
Behavioral: Somnolence (general depressed activity) | Blood: Other changes
TOVEFN (1),39,2000
|
inhalation | rat
lowest published toxic concentration: 4.1 mg/m3/4 hour
|
Behavioral: Altered sleep time (including change in righting reflex) | Behavioral: Somnolence (general depressed activity) Kidney, Ureter, and Bladder: Other changes in urine composition
TOVEFN (1),40,2000
|
intramuscular | infant
lowest published toxic dose: 50 mg/kg
|
Behavioral: Coma
|
PEDIAU 77,848,1986
|
intramuscular | mouse
lethal dose (50 percent kill): 175 mg/kg
|
N/R
|
YAKUD5 23,2215,1981
|
intraperitoneal | mouse
lethal dose (50 percent kill): 88 mg/kg
|
N/R
|
PHARAT 52,926,1997
|
intraperitoneal | mouse
lowest published toxic dose: 80 mg/kg
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TXAPA9 71,254,1983
|
intraperitoneal | mouse
lowest published toxic dose: 50 mg/kg
|
Behavioral: Altered sleep time (including change in righting reflex)
|
FATOAO 53,52,1990
|
intraperitoneal | mouse
lowest published toxic dose: 190 µg/kg
|
Behavioral: Convulsions or effect on seizure threshold
|
CYLPDN 22,361,2001
|
intraperitoneal | mouse
lowest published toxic dose: 46 mg/kg
|
Behavioral: Change in motor activity (specific assay)
|
PCJOAU 35,127,2001
|
intraperitoneal | mouse
lowest published toxic dose: 2.5 mg/kg
|
Peripheral Nerve and Sensation: Sensory change involving segmental distribution
|
BJMRDK 34,397,2001
|
intraperitoneal | mouse
lowest published toxic dose: 84.5 mg/kg
|
Behavioral: Change in motor activity (specific assay) | Behavioral: Ataxia
EURNE* 15,609,2005
|
intraperitoneal | mouse
lowest published toxic dose: 1.3 mg/kg
|
Behavioral: Anticonvulsant
|
AEPPAE 370,99,2004
|
intraperitoneal | mouse
lowest published toxic dose: 30 mg/kg
|
Behavioral: Antianxiety
|
JPHSC* 104,153,2007
|
intraperitoneal | mouse
lowest published toxic dose: 20 mg/kg
|
Behavioral: Sleep
|
FTRPAE 70,25,1999
|
intraperitoneal | rat
lethal dose (50 percent kill): 110 mg/kg
|
N/R
|
FMXXAJ #7157M
|
intraperitoneal | rat
lowest published toxic dose: 80 mg/kg
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
APTOA6 46,353,1980
|
intraperitoneal | rat
lowest published toxic dose: 100 mg/kg
|
Endocrine: Change in gonadotropins | Endocrine: Change in LH
LIFSAK 23,1507,1978
|
intraperitoneal | rat
lowest published toxic dose: 80 mg/kg
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes
FATOAO 44,208,1981
|
intraperitoneal | rat
lowest published toxic dose: 5 mg/kg
|
Peripheral Nerve and Sensation: Sensory change involving segmental distribution
|
BJMRDK 34,397,2001
|
intraperitoneal | rat
lowest published toxic dose: 25 mg/kg
|
Behavioral: Anticonvulsant
|
ARTODN 79,610,2005
|
intraperitoneal | rat
lowest published toxic dose: 40 mg/kg
|
Endocrine: Change in LH | Reproductive: Maternal effects: Oogenesis
TOXID9 66,343,2002
|
intraperitoneal | rat
lowest published toxic dose: 80 mg/kg
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TXCYAC 216,147,2005
|
intraperitoneal | rat
lowest published toxic dose: 120 mg/kg
|
Liver: Other changes | Biochemical: Metabolism (intermediary): Other proteins Biochemical: Metabolism (intermediary): Other
TXCYAC 213,237,2005
|
intraperitoneal | rabbit
lowest published lethal dose: 150 mg/kg
|
N/R
|
JPETAB 44,325,1932
|
intraspinal | rat
lowest published toxic dose: 20 µg/kg
|
Behavioral: Analgesia
|
BJMRDK 34,397,2001
|
intravenous | mouse
lethal dose (50 percent kill): 218 mg/kg
|
Peripheral Nerve and Sensation: Local anesthetic
|
AIPTAK 191,405,1971
|
intravenous | rat
lethal dose (50 percent kill): 209 mg/kg
|
N/R
|
ARTODN 40,211,1978
|
intravenous | rat
lowest published toxic dose: 40 mg/kg
|
Brain and Coverings: Recordings from specific areas of CNS
|
EJPHAZ 466,255,2003
|
intravenous | rabbit
lethal dose (50 percent kill): 187 mg/kg
|
Behavioral: Convulsions or effect on seizure threshold | Lung, Thorax, or Respiration: Respiratory stimulation
ARZNAD 33,1168,1983
|
oral | cat
lowest published lethal dose: 125 mg/kg
|
N/R
|
HBAMAK 4,1289,1935
|
oral | child
lowest published toxic dose: 20 mg/kg/ intermittent
|
Eye: Other eye effects | Behavioral: Ataxia Behavioral: Muscle contraction or spasticity
CPEDAM 31,252,1992
|
oral | child
lowest published toxic dose: 10 mg/kg
|
Behavioral: Somnolence (general depressed activity) | Behavioral: Ataxia
AJDCAI 130,507,1976
|
oral | dog
lethal dose (50 percent kill): 150 mg/kg
|
Behavioral: Somnolence (general depressed activity)
|
SMWOAS 85,305,1955
|
oral | guinea pig
lethal dose (50 percent kill): 130 mg/kg
|
N/R
|
AIPTAK 91,437,1952
|
oral | human
lowest published toxic dose: 18 mg/kg
|
Lung, Thorax, or Respiration: Other changes | Skin: After systemic exposure: Dermatitis, other Nutritional and Gross Metabolic: Body temperature increase
JAMAAP 116,700,1941
|
oral | man
lowest published lethal dose: 6,485 µg/kg/2 week- intermittent
|
Skin: After systemic exposure: Dermatitis, allergic | Nutritional and Gross Metabolic: Body temperature increase
AIMEAS 13,1243,1940
|
oral | mouse
lethal dose (50 percent kill): 137 mg/kg
|
N/R
|
PCJOAU 10,41,1976
|
oral | mouse
lowest published toxic dose: 11.7 mg/kg
|
Behavioral: Anticonvulsant
|
EKFAE9 58,19,1995
|
oral | mouse
lowest published toxic dose: 12.8 mg/kg
|
Behavioral: Ataxia
|
JPETAB 308,127,2004
|
oral | mouse
lowest published toxic dose: 41.7 mg/kg
|
Behavioral: Convulsions or effect on seizure threshold
|
JPETAB 308,127,2004
|
oral | mouse
lethal dose (50 percent kill): 112 mg/kg
|
Behavioral: Somnolence (general depressed activity) | Behavioral: Convulsions or effect on seizure threshold Behavioral: Muscle weakness
TOVEFN (1),40,2000
|
oral | mouse
lethal dose (50 percent kill): 112 mg/kg
|
Lung, Thorax, or Respiration: Respiratory depression | Nutritional and Gross Metabolic: Weight loss or decreased weight gain Nutritional and Gross Metabolic: Body temperature decrease
TOVEFN (1),40,2000
|
oral | mouse
lowest published toxic dose: 100 mg/kg
|
Liver: Other changes | Biochemical: Metabolism (intermediary): Lipids including transport Biochemical: Metabolism (intermediary): Other
TOXID9 -,170,2008
|
oral | rat
lethal dose (50 percent kill): 162 mg/kg
|
N/R
|
TXAPA9 18,185,1971
|
oral | rat
lowest published toxic dose: 50 mg/kg
|
Liver: Changes in liver weight | Endocrine: Changes in adrenal weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TXCYAC 188,171,2003
|
oral | rat
lowest published toxic dose: 20 mg/kg
|
Behavioral: Sleep
|
PSCHDL 173,203,2004
|
oral | rat
lowest published toxic dose: 50 mg/kg
|
Brain and Coverings: Recordings from specific areas of CNS | Behavioral: Sleep Behavioral: Altered sleep time (including change in righting reflex)
PSCHDL 173,203,2004
|
oral | rat
lowest published toxic dose: 100 mg/kg
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
|
TOLED5 145,281,2003
|
oral | rat
lowest published toxic dose: 60 mg/kg
|
Behavioral: Somnolence (general depressed activity)
|
EJPHAZ 494,147,2004
|
oral | rat
lowest published toxic dose: 10 mg/kg
|
Behavioral: Altered sleep time (including change in righting reflex)
|
PSCHDL 173,203,2004
|
oral | rat
lowest published toxic dose: 10 mg/kg
|
Liver: Other changes | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Metabolism (intermediary): Lipids including transport
TOLED5 150,157,2004
|
oral | rat
lowest published toxic dose: 7 mg/kg
|
Reproductive: Other effects on male
|
JPETAB 308,127,2004
|
oral | rat
lethal dose (50 percent kill): 213 mg/kg
|
Behavioral: Somnolence (general depressed activity) | Behavioral: Convulsions or effect on seizure threshold Behavioral: Muscle weakness
TOVEFN (1),40,2000
|
oral | rat
lethal dose (50 percent kill): 213 mg/kg
|
Lung, Thorax, or Respiration: Respiratory depression | Nutritional and Gross Metabolic: Body temperature decrease
TOVEFN (1),40,2000
|
oral | rat
lowest published toxic dose: 92.8 mg/kg
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
TXCYAC 239,127,2007
|
oral | rat
lowest published toxic dose: 20 mg/kg
|
Behavioral: Anticonvulsant
|
AEPPAE 370,99,2004
|
oral | rabbit
lethal dose (50 percent kill): 185 mg/kg
|
N/R
|
NUPOBT 15,545,1977
|
oral | woman
lowest published toxic dose: 46 mg/kg
|
Behavioral: Coma | Lung, Thorax, or Respiration: Dyspnea
CPEDAM 24,678,1985
|
oral | woman
lowest published lethal dose: 25,272 µg/kg/13 day- intermittent
|
Behavioral: Coma | Skin: After systemic exposure: Dermatitis, allergic Nutritional and Gross Metabolic: Body temperature increase
CMAJAX 33,635,1935
|
parenteral | rat
lowest published toxic dose: 111 µg/kg
|
Behavioral: Analgesia
|
EJPHAZ 483,233,2004
|
rectal | rat
lethal dose (50 percent kill): 284 mg/kg
|
Behavioral: Change in motor activity (specific assay) | Nutritional and Gross Metabolic: Body temperature decrease Behavioral: General anesthetic
AACRAT 46,395,1967
|
subcutaneous | cat
lowest published lethal dose: 125 mg/kg
|
N/R
|
HBAMAK 4,1289,1935
|
subcutaneous | dog
lowest published lethal dose: 150 mg/kg
|
N/R
|
HBAMAK 4,1289,1935
|
subcutaneous | frog
lowest published lethal dose: 500 mg/kg
|
N/R
|
HBAMAK 4,1289,1935
|
subcutaneous | hamster
lowest published toxic dose: 100 mg/kg
|
Endocrine: Effect on menstrual cycle | Reproductive: Maternal effects: Oogenesis Reproductive: Maternal effects: Ovaries, fallopian tubes
TXAPA9 121,279,1993
|
subcutaneous | mouse
lethal dose (50 percent kill): 228 mg/kg
|
N/R
|
ARZNAD 30,477,1980
|
subcutaneous | mouse
lowest published toxic dose: 40 mg/kg
|
Immunological Including Allergic: Increase in cellular immune response
|
TXCYAC 188,29,2003
|
subcutaneous | rat
lethal dose (50 percent kill): 200 mg/kg
|
N/R
|
AEPPAE 152,341,1930
|
subcutaneous | rat
lowest published toxic dose: 12.5 mg/kg
|
Vascular: BP lowering not characterized in autonomic section
|
PHTOEH 86,59,2000
|
subcutaneous | rabbit
lowest published lethal dose: 150 mg/kg
|
N/R
|
JACSAT 45,243,1923
|
unreported route | mammal (species unspecified)
lethal dose (50 percent kill): 320 mg/kg
|
N/R
|
RUXXAF #1589585
|
unreported route | mouse
lowest published toxic dose: 3.6 mg/kg
|
Behavioral: Anticonvulsant
|
FATOAO 55,27,1992
|
unreported route | mouse
lowest published toxic dose: 96 mg/kg
|
Behavioral: Ataxia
|
FATOAO 55,27,1992
|
unreported route | rat
lowest published toxic dose: 100 mg/kg
|
Liver: Hepatitis (hepatocellular necrosis), zonal | Liver: Other changes
TOXID9 66,10,2002
|
| |||
OTHER MULTIPLE DOSE DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
intraperitoneal | hamster
lowest published toxic dose: 560 mg/kg/7 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
|
ABBIA4 134,76,1969
|
intraperitoneal | mouse
lowest published toxic dose: 300 mg/kg/5 day- intermittent
|
Brain and Coverings: Other degenerative changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes
BJPCBM 126,1634,1999
|
intraperitoneal | mouse
lowest published toxic dose: 300 mg/kg/3 day- intermittent
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
BCPCA6 62,161,2001
|
intraperitoneal | mouse
lowest published toxic dose: 160 mg/kg/4 day- intermittent
|
Gastrointestinal: Changes in structure or function of salivary glands | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
BCPCA6 62,249,2001
|
intraperitoneal | mouse
lowest published toxic dose: 150 mg/kg/3 day- intermittent
|
Behavioral: Altered sleep time (including change in righting reflex)
|
FATOAO 52,53,1989
|
intraperitoneal | mouse
lowest published toxic dose: 80 mg/kg/4 day- intermittent
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TXAPA9 180,1,2002
|
intraperitoneal | quail
lowest published toxic dose: 750 mg/kg/5 day- intermittent
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
JTEHD6 15,93,1985
|
intraperitoneal | rat
lowest published toxic dose: 240 mg/kg/3 day- intermittent
|
Liver: Changes in liver weight | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases
ARZNAD 40,239,1990
|
intraperitoneal | rat
lowest published toxic dose: 600 mg/kg/12 day- intermittent
|
Liver: Changes in liver weight | Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
NTIS** OTS0590101
|
intraperitoneal | rat
lowest published toxic dose: 300 mg/kg/4 day- intermittent
|
Liver: Changes in liver weight | Endocrine: Evidence of thyroid hypofunction Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
TXAPA9 111,99,1991
|
intraperitoneal | rat
lowest published toxic dose: 300 mg/kg/4 day- intermittent
|
Liver: Changes in liver weight | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
TXAPA9 111,99,1991
|
intraperitoneal | rat
lowest published toxic dose: 250 mg/kg/5 day- intermittent
|
Liver: Change in gall bladder structure or function | Liver: Other changes Biochemical: Metabolism (intermediary): Other
BCPCA6 17,1049,1968
|
intraperitoneal | rat
lowest published toxic dose: 372 mg/kg/4 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) | Biochemical: Metabolism (intermediary): Other
GEPHDP 18,165,1987
|
intraperitoneal | rat
lowest published toxic dose: 278.7 mg/kg/3 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) | Biochemical: Metabolism (intermediary): Other
CJPPA3 63,1537,1985
|
intraperitoneal | rat
lowest published toxic dose: 160 mg/kg/2 day- intermittent
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation) Biochemical: Metabolism (intermediary): Other proteins
BCPCA6 63,333,2002
|
intraperitoneal | rat
lowest published toxic dose: 160 mg/kg/8 day- intermittent
|
Biochemical: Neurotransmitters or modulators (putative): Catecholamine levels in sympathetic nerves | Biochemical: Neurotransmitters or modulators (putative): Dopamine in striatum
PCJOAU 37,4,2003
|
intraperitoneal | rat
lowest published toxic dose: 300 mg/kg/4 day- intermittent
|
Liver: Liver function tests impaired
|
TXAPA9 180,56,2002
|
intraperitoneal | rat
lowest published toxic dose: 300 mg/kg/4 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
|
CBINA8 146,285,2003
|
intraperitoneal | rat
lowest published toxic dose: 400 mg/kg/4 day- intermittent
|
Liver: Other changes | Liver: Changes in liver weight Biochemical: Metabolism (intermediary): Other
JAPTO* 23,453,2003
|
intraperitoneal | rat
lowest published toxic dose: 240 mg/kg/3 day- intermittent
|
Liver: Other changes | Endocrine: Differential effect of sex or castration on observed toxicity Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
CRTOEC 16,768,2003
|
intraperitoneal | rat
lowest published toxic dose: 320 mg/kg/4 day- intermittent
|
Liver: Other changes | Endocrine: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
TOXID9 90,25,2006
|
intraperitoneal | rat
lowest published toxic dose: 400 mg/kg/5 day- intermittent
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects
TOXID9 90,374,2006
|
intraperitoneal | rat
lowest published toxic dose: 150 mg/kg/3 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
|
ACPSI* 24,831,2003
|
intraperitoneal | rat
lowest published toxic dose: 400 mg/kg/5 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
|
TXAPA9 219,72,2007
|
intraperitoneal | rat
lowest published toxic dose: 400 mg/kg/5 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
TXAPA9 231,10,2008
|
oral | dog
lowest published toxic dose: 840 mg/kg/3 week- intermittent
|
Nutritional and Gross Metabolic: Weight loss or decreased weight gain | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Phosphatases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
TOPADD 15,49,2002
|
oral | dog
lowest published toxic dose: 80 mg/kg/8 day- intermittent
|
Kidney, Ureter, and Bladder: Other changes
|
FATOAO 53,48,1990
|
oral | dog
lowest published toxic dose: 80 mg/kg/4 day- intermittent
|
Kidney, Ureter, and Bladder: Other changes
|
FATOAO 53,48,1990
|
oral | monkey
lowest published toxic dose: 260 mg/kg/13 day- intermittent
|
Brain and Coverings: Other degenerative changes | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
EJPHAZ 552,151,2006
|
oral | monkey
lowest published toxic dose: 440 mg/kg/22 day- intermittent
|
Brain and Coverings: Other degenerative changes | Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases
BJPCBM 148,786,2006
|
oral | mouse
lowest published toxic dose: 28 gm/kg/40 week- continuous
|
Liver: Other changes | Liver: Changes in liver weight
TXAPA9 96,494,1988
|
oral | mouse
lowest published toxic dose: 1,120 mg/kg/14 day- intermittent
|
Liver: Other changes | Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TXAPA9 155,1,1999
|
oral | mouse
lowest published toxic dose: 210 mg/kg/3 day- intermittent
|
Behavioral: Altered sleep time (including change in righting reflex) | Liver: Changes in liver weight Immunological Including Allergic: Hypersensitivity delayed (multiple organ involvement)
FATOAO 55,46,1992
|
oral | mouse
lowest published toxic dose: 1,512 mg/kg/21 day- intermittent
|
Liver: Changes in liver weight | Endocrine: Evidence of thyroid hypofunction Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
TXAPA9 188,6,2003
|
oral | mouse
lowest published toxic dose: 600 mg/kg/10 day- continuous
|
Liver: Other changes
|
TOXID9 72,239,2003
|
oral | mouse
lowest published toxic dose: 180 mg/kg/3 day- continuous
|
Liver: Other changes
|
TOXID9 72,239,2003
|
oral | mouse
lowest published toxic dose: 1,400 mg/kg/14 day- continuous
|
Liver: Other changes | Biochemical: Metabolism (intermediary): Other
TOXID9 60,158,2001
|
oral | mouse
lowest published toxic dose: 27,300 mg/kg/26 week- intermittent
|
Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
|
TOXID9 60,278,2001
|
oral | mouse
lowest published toxic dose: 27,300 mg/kg/26 week- continuous
|
Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
|
TOXID9 60,278,2001
|
oral | mouse
lowest published toxic dose: 1,820 mg/kg/26 week- intermittent
|
Liver: Other changes
|
TOXID9 60,278,2001
|
oral | mouse
lowest published toxic dose: 13,650 mg/kg/26 week- continuous
|
Liver: Other changes
|
TOXID9 60,278,2001
|
oral | mouse
lowest published toxic dose: 420 mg/kg/1 week- continuous
|
Liver: Other changes
|
TOXID9 60,286,2001
|
oral | mouse
lowest published toxic dose: 30 mg/kg/3 day- intermittent
|
Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TOXID9 90,37,2006
|
oral | mouse
lowest published toxic dose: 300 mg/kg/3 day- intermittent
|
Liver: Changes in liver weight | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TOXID9 90,37,2006
|
oral | mouse
lowest published toxic dose: 1,610 mg/kg/1 week- continuous
|
Liver: Hepatitis (hepatocellular necrosis), zonal | Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TXAPA9 214,178,2006
|
oral | mouse
lowest published toxic dose: 840 mg/kg/2 week- continuous
|
Liver: Other changes
|
NSAPCC 369(Suppl 1),R129,2004
|
oral | mouse
lowest published toxic dose: 630 mg/kg/7 day- intermittent
|
Liver: Other changes | Biochemical: Metabolism (intermediary): Lipids including transport Biochemical: Metabolism (intermediary): Other
TOXID9 -,170,2008
|
oral | mouse
lowest published toxic dose: 2,520 mg/kg/28 day- intermittent
|
Liver: Other changes | Biochemical: Metabolism (intermediary): Lipids including transport Biochemical: Metabolism (intermediary): Other
TOXID9 -,170,2008
|
oral | mouse
lowest published toxic dose: 10.5 mg/kg/7 day- intermittent
|
Liver: Other changes | Kidney, Ureter, and Bladder: Other changes Blood: Changes in spleen
FCTOD7 46,1474,2008
|
oral | mouse
lowest published toxic dose: 600 mg/kg/3 day- continuous
|
Liver: Changes in liver weight | Liver: Other changes
TXAPA9 226,338,2008
|
oral | mouse
lowest published toxic dose: 600 mg/kg/10 day- continuous
|
Nutritional and Gross Metabolic: Weight loss or decreased weight gain
|
TXAPA9 226,338,2008
|
oral | rat
lowest published toxic dose: 252 mg/kg/7 day- continuous
|
Endocrine: Evidence of thyroid hyperfunction | Endocrine: Other changes Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)
TXAPA9 160,163,1999
|
oral | rat
lowest published toxic dose: 8,400 mg/kg/12 week- continuous
|
Liver: Other changes | Liver: Changes in liver weight
TOSCF2 44,46,1998
|
oral | rat
lowest published toxic dose: 1,120 mg/kg/14 day- intermittent
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
TXAPA9 155,1,1999
|
oral | rat
lowest published toxic dose: 6,480 mg/kg/90 day- continuous
|
Behavioral: Food intake (animal) | Liver: Changes in liver weight Endocrine: Changes in thyroid weight
TOSCF2 50,45,1999
|
oral | rat
lowest published toxic dose: 420 mg/kg/4 week- intermittent
|
Kidney, Ureter, and Bladder: Other changes in urine composition | Blood: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
TOVEFN (1),39,2000
|
oral | rat
lowest published toxic dose: 240 mg/kg/3 day- continuous
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects
|
FCTOD7 39,541,2001
|
oral | rat
lowest published toxic dose: 1.4 gm/kg/4 week- continuous
|
Liver: Other changes | Liver: Changes in liver weight Endocrine: Changes in thyroid weight
TXAPA9 172,83,2001
|
oral | rat
lowest published toxic dose: 3,150 mg/kg/15 week- continuous
|
Liver: Changes in liver weight | Endocrine: Changes in thyroid weight
TXAPA9 94,254,1988
|
oral | rat
lowest published toxic dose: 3,150 mg/kg/15 week- continuous
|
Liver: Changes in liver weight | Endocrine: Other changes
TXAPA9 94,254,1988
|
oral | rat
lowest published toxic dose: 1,050 mg/kg/14 day- intermittent
|
Liver: Changes in liver weight | Endocrine: Evidence of thyroid hyperfunction Endocrine: Changes in thyroid weight
TXAPA9 111,263,1991
|
oral | rat
lowest published toxic dose: 350 mg/kg/7 day- intermittent
|
Endocrine: Other changes
|
TXAPA9 111,263,1991
|
oral | rat
lowest published toxic dose: 1,400 mg/kg/2 week- continuous
|
Liver: Changes in liver weight | Endocrine: Changes in thyroid weight Endocrine: Other changes
TXAPA9 99,216,1989
|
oral | rat
lowest published toxic dose: 1,400 mg/kg/2 week- continuous
|
Liver: Changes in liver weight | Endocrine: Other changes
TXAPA9 99,216,1989
|
oral | rat
lowest published toxic dose: 8,400 mg/kg/12 week- continuous
|
Nutritional and Gross Metabolic: Weight loss or decreased weight gain | Endocrine: Changes in thyroid weight
TXAPA9 99,216,1989
|
oral | rat
lowest published toxic dose: 2,800 mg/kg/4 week- continuous
|
Biochemical: Metabolism (intermediary): Other | Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
TXAPA9 99,216,1989
|
oral | rat
lowest published toxic dose: 1,120 mg/kg/14 day- intermittent
|
Liver: Multiple effects | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects
AMACCQ 44,123,2000
|
oral | rat
lowest published toxic dose: 125 mg/kg/5 day- intermittent
|
Blood: Luekopenia | Immunological Including Allergic: Decrease in humoral immune response Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
FATOAO 50,52,1987
|
oral | rat
lowest published toxic dose: 125 mg/kg/5 day- intermittent
|
Behavioral: Altered sleep time (including change in righting reflex) | Immunological Including Allergic: Decrease in humoral immune response Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
FATOAO 50,52,1987
|
oral | rat
lowest published toxic dose: 750 mg/kg/30 day- intermittent
|
Immunological Including Allergic: Increase in humoral response
|
FATOAO 50,52,1987
|
oral | rat
lowest published toxic dose: 1,400 mg/kg/2 week- intermittent
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases Biochemical: Metabolism (intermediary): Other proteins
JTSCDR 25,121,2000
|
oral | rat
lowest published toxic dose: 1,400 mg/kg/2 week- intermittent
|
Liver: Changes in liver weight | Endocrine: Evidence of thyroid hypofunction Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
JTSCDR 25,121,2000
|
oral | rat
lowest published toxic dose: 200 mg/kg/4 day- intermittent
|
Kidney, Ureter, and Bladder: Other changes
|
FATOAO 54,35,1991
|
oral | rat
lowest published toxic dose: 1,400 mg/kg/2 week- intermittent
|
Liver: Changes in liver weight
|
TOXID9 72,284,2003
|
oral | rat
lowest published toxic dose: 70 mg/kg/14 day- intermittent
|
Behavioral: Convulsions or effect on seizure threshold | Behavioral: Withdrawal
EURNE* 12,S60,2002
|
oral | rat
lowest published toxic dose: 300 mg/kg/5 day- intermittent
|
Liver: Other changes
|
TOXID9 72,360,2003
|
oral | rat
lowest published toxic dose: 4,032 mg/kg/28 day- continuous
|
Liver: Other changes
|
TOXID9 72,235,2003
|
oral | rat
lowest published toxic dose: 375 mg/kg/15 day- intermittent
|
Liver: Changes in liver weight
|
TOSCF2 69,79,2002
|
oral | rat
lowest published toxic dose: 1,500 mg/kg/15 day- intermittent
|
Liver: Changes in liver weight | Endocrine: Changes in spleen weight Reproductive: Paternal effects: Testes, epididymis, sperm duct
TOSCF2 69,79,2002
|
oral | rat
lowest published toxic dose: 300 mg/kg/5 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
|
CBINA8 147,151,2004
|
oral | rat
lowest published toxic dose: 200 mg/kg/2 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
|
TOLED5 145,281,2003
|
oral | rat
lowest published toxic dose: 4,550 mg/kg/26 week- continuous
|
Liver: Other changes | Biochemical: Metabolism (intermediary): Other
TOXID9 44,155,2005
|
oral | rat
lowest published toxic dose: 40 mg/kg/4 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
|
TOXID9 44,100,2005
|
oral | rat
lowest published toxic dose: 1,400 mg/kg/14 day- intermittent
|
Liver: Changes in liver weight | Endocrine: Other changes Endocrine: Changes in thyroid weight
TOXID9 60,227,2001
|
oral | rat
lowest published toxic dose: 750 mg/kg/30 day- intermittent
|
Liver: Changes in liver weight
|
NTPTR* RACB-20103
|
oral | rat
lowest published toxic dose: 3,000 mg/kg/30 day- intermittent
|
Endocrine: Changes in pituitary weight | Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands Nutritional and Gross Metabolic: Weight loss or decreased weight gain
NTPTR* RACB-20103
|
oral | rat
lowest published toxic dose: 500 mg/kg/20 day- intermittent
|
Liver: Changes in liver weight | Endocrine: Changes in adrenal weight
NTPTR* RACB-20103
|
oral | rat
lowest published toxic dose: 2,000 mg/kg/20 day- intermittent
|
Endocrine: Changes in thyroid weight
|
NTPTR* RACB-20103
|
oral | rat
lowest published toxic dose: 210 mg/kg/14 day- intermittent
|
Kidney, Ureter, and Bladder: Other changes in urine composition | Blood: Changes in other cell count (unspecified) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases
TOVEFN (1),40,2000
|
oral | rat
lowest published toxic dose: 420 mg/kg/30 day- intermittent
|
Behavioral: Altered sleep time (including change in righting reflex) | Liver: Other changes Kidney, Ureter, and Bladder: Incontinence
TOVEFN (1),40,2000
|
oral | rat
lowest published toxic dose: 240 mg/kg/3 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)
|
MUTAEX 19,245,2004
|
oral | rat
lowest published toxic dose: 2.1 gm/kg/6 week- continuous
|
Liver: Other changes | Endocrine: Changes in adrenal weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases
JPETAB 317,590,2006
|
oral | rat
lowest published toxic dose: 9.8 gm/kg/28 week- continuous
|
Tumorigenic: Protects against induction of experimental tumors
|
JPETAB 317,590,2006
|
oral | rat
lowest published toxic dose: 278.4 mg/kg/3 day- intermittent
|
Liver: Changes in liver weight
|
TXCYAC 239,127,2007
|
oral | rat
lowest published toxic dose: 1,050 mg/kg/1 week- intermittent
|
Behavioral: Antianxiety | Behavioral: Tolerance
TOPADD 33,118,2005
|
oral | rat
lowest published toxic dose: 1,000 mg/kg/5 day- intermittent
|
Liver: Other changes | Liver: Changes in liver weight
TOPADD 33,118,2005
|
oral | rat
lowest published toxic dose: 1,050 mg/kg/14 day- intermittent
|
Biochemical: Metabolism (intermediary): Other proteins
|
NSAPCC 372(Suppl 1),122,2006
|
oral | rat
lowest published toxic dose: 2,695 mg/kg/11 week- continuous
|
Liver: Other changes | Liver: Changes in liver weight
JTPAE7 17,267,2004
|
oral | rat
lowest published toxic dose: 420 mg/kg/2 week- continuous
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases
JTPAE7 19,37,2006
|
oral | rat
lowest published toxic dose: 1,400 mg/kg/14 day- continuous
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases
BIJOAK 300,117,1994
|
oral | rabbit
lowest published toxic dose: 256.4 mg/kg/14 day- intermittent
|
Liver: Jaundice (or hyperbilirubinemia) hepatocellular | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)
CEXPB9 27,987,2000
|
oral | woman
lowest published toxic dose: 28 mg/kg/7 day- intermittent
|
Blood: Thrombocytopenia
|
APHRER 39,1367,2005
|
subcutaneous | rat
lowest published toxic dose: 280 mg/kg/7 day- intermittent
|
Liver: Other changes | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects
JPETAB 293,1027,2000
|
subcutaneous | rat
lowest published toxic dose: 150 mg/kg/5 day- intermittent
|
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) | Biochemical: Metabolism (intermediary): Other
JTEHD6 45,47,1995
|
skin | mouse
lowest published toxic dose: 21,840 mg/kg/26 week- intermittent
|
Liver: Other changes
|
TOXID9 60,278,2001
|
unreported route | human
lowest published toxic dose: 35.7 mg/kg/3 week- intermittent
|
Blood: Eosinophilia
|
CLPTAT 14,727,1976
|
unreported route | mouse
lowest published toxic dose: 200 mg/kg/4 day- intermittent
|
Related to Chronic Data: Changes in uterine weight
|
CLPTAT 14,727,1976
|
unreported route | rat
lowest published toxic dose: 1,400 mg/kg/2 week- intermittent
|
Liver: Other changes | Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes
PHTOEH 73(Suppl 2),113,1993
|
unreported route | rat
lowest published toxic dose: 4,800 mg/kg/60 day- intermittent
|
Liver: Other changes | Liver: Tumors Tumorigenic: Increased incidence of tumors in susceptible strains
TOXID9 78,115,2004
|
unreported route | rat
lowest published toxic dose: 600 mg/kg/5 day- intermittent
|
Liver: Other changes
|
TOXID9 66,301,2002
|
unreported route | rat
lowest published toxic dose: 1,400 mg/kg/14 day- intermittent
|
Liver: Other changes | Endocrine: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation)
TOXID9 66,342,2002
|
| |||
REVIEWS:
ORGANIZATION
|
STANDARD
|
|
REFERENCE
International Agency for Research on Cancer (IARC) Cancer Review
|
Animal Sufficient Evidence
|
IMEMDT 79,-,2000
|
International Agency for Research on Cancer (IARC) Cancer Review
|
Human Inadequate Evidence
|
IMEMDT 79,-,2000
|
International Agency for Research on Cancer (IARC) Cancer Review
|
Group 2B
|
IMEMDT 79,-,2000
|
TOXICOLOGY REVIEW
|
|
NEJMAG 343,1608,2000
|
TOXICOLOGY REVIEW
|
|
PLMJAP 6,160,1975
|
TOXICOLOGY REVIEW
|
|
AUHPAI 4(1),5,1974
|
TOXICOLOGY REVIEW
|
|
JRPMAP 12,27,1974
|
TOXICOLOGY REVIEW
|
|
PHREA7 19,472,1939
|
TOXICOLOGY REVIEW
|
|
EPILAK 16,159,1975
|
TOXICOLOGY REVIEW
|
|
PRSMA4 63,48,1970
|
TOXICOLOGY REVIEW
|
|
TPHSDY 24,55,2003
|
TOXICOLOGY REVIEW
|
|
BMJOAE 2,442,1973
|
TOXICOLOGY REVIEW
|
|
TPHSDY 24,542,2003
|
TOXICOLOGY REVIEW
|
|
REPTED 22,214,2006
|
TOXICOLOGY REVIEW
|
|
REPTED 22,196,2006
|
TOXICOLOGY REVIEW
|
|
AJDCAI 131,1337,1977
|
TOXICOLOGY REVIEW
|
|
NRTXDN 7,287,1986
|
TOXICOLOGY REVIEW
|
|
ETOPFR 9,117,2001
|
TOXICOLOGY REVIEW
|
|
ARPTDI 44,87,2004
|
TOXICOLOGY REVIEW
|
|
TPHSDY 23,113,2002
|
TOXICOLOGY REVIEW
|
|
TPHSDY 24,199,2003
|
TOXICOLOGY REVIEW
|
|
DIMON* 39,678,1993
|
TOXICOLOGY REVIEW
|
|
ENTOX* -,209,2005
|
TOXICOLOGY REVIEW
|
|
MUREAV 584,1,2005
|
TOXICOLOGY REVIEW
|
|
HETOEA 25,413,2006
|
TOXICOLOGY REVIEW
|
|
TOPADD 32(Suppl. 2),85,2004
|
TOXICOLOGY REVIEW
|
|
TOPADD 33,63,2005
|
TOXICOLOGY REVIEW
|
|
TOPADD 32(Suppl. 2),71,2004
|
TOXICOLOGY REVIEW
|
|
AJEMEN 22,404,2004
|
TOXICOLOGY REVIEW
|
|
MUREAV 654,114,2008
|
TOXICOLOGY REVIEW
|
|
PAREAQ 56,103,2004
|
TOXICOLOGY REVIEW
|
|
MUREAV 654,114,2008
|
TOXICOLOGY REVIEW
|
|
JTPAE7 19,57,2006
|
TOXICOLOGY REVIEW
|
|
JTPAE7 19,111,2006
|
TOXICOLOGY REVIEW
|
|
JTPAE7 19,155,2006
|
TOXICOLOGY REVIEW
|
|
JTPAE7 19,1,2006
|
TOXICOLOGY REVIEW
|
|
JAADDB 56,181,2007
|
TOXICOLOGY REVIEW
|
|
HUTOX* -,319,1996
|
TOXICOLOGY REVIEW
|
|
REPTED 26,42,2008
|
TOXICOLOGY REVIEW
|
|
TXCYAC 254,184,2008
|
| ||
STANDARDS AND REGULATIONS:
ORGANIZATION
|
STANDARD
|
|
REFERENCE
Occupational Exposure Limit - RUSSIA
|
short term exposure limit 0.1 mg/m3, JUN2003
|
| |||
NIOSH DOCUMENTATION AND SURVEILLANCE:
ORGANIZATION
|
STANDARD or SURVEY
|
|
REFERENCE
National Occupational Hazard Survey 1974
|
National Occupational Hazard Survey 1974: Hazard Code: 84369; | Number of Industries 4; Total Number of Facilities 3,360; Number of Occupations 22; Total Number of Employees Exposed 15,081
National Occupational Exposure Survey 1983
|
National Occupational Exposure Survey 1983: Hazard Code: 84369 |
Number of Industries 4; Total Number of Facilities 810; Number of Occupations 14; Total Number of Employees Exposed 22,924; Total Number of Female Employees Exposed 17,005 | ||||
STATUS IN FEDERAL AGENCIES:
ORGANIZATION
|
|
REFERENCE
EPA GENETOX PROGRAM 1988, Negative: SHE-clonal assay; Sperm morphology-mouse
|
EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus
|
Used as a drug for the treatment of epilepsy, and as hypnotics and sedatives
|
EPA TSCA Section 8(d) unpublished health/safety studies
|
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
|
| ||||||
REFERENCES:
CODEN
|
|
REFERENCE
53HJAC
|
"Mouse Liver Neoplasia: Current Perspectives," Popp, J.A., ed., New York, Hemisphere Pub.
Corp., 1984
|
AACRAT
|
Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave.,
New York, NY 10017) V.36- 1957-
|
ABBIA4
|
Archives of Biochemistry and Biophysics. (Academic Press, Inc., 1 E. First St., Duluth, MN
55802) V.31- 1951-
|
ACATA5
|
Acta Anatomica. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1945-
|
ACPSI*
|
Acta pharmacologica Sinica (Shanghai : Shanghai Institute of Materia Medica : Chinese Academy
of Science ; Carlton, VIC, Australia : Blackwell Publishing Asia, 2005) V.21- 2000-
|
AEPPAE
|
Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. (Berlin, Ger.)
V.110-253, 1925-66. For publisher information, see NSAPCC.
|
AIMEAS
|
Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA
19104) V.1- 1927-
|
AIPTAK
|
Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of
Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898-
|
AJANA2
|
American Journal of Anatomy. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003)
V.1-192, 1901-91.
|
AJDCAI
|
American Journal of Diseases of Children. (AMA, 535 N. Dearborn St., Chicago, IL 60610)
V.1-80(3), 1911-50; V.100- 1960-
|
AJEMEN
|
American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983-
|
AJOGAH
|
American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial
Dr., St. Louis, MO 63146) V.1- 1920-
|
AMACCQ
|
Antimicrobial Agents and Chemotherapy. (American Soc. for Microbiology, 1913 I St., NW,
Washington, DC 20006) V.1- 1972-
|
APHRER
|
Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26-
1992-
|
APTOA6
|
Acta Pharmacologica et Toxicologica. (Copenhagen, Denmark) V.1-59, 1945-86. For publisher
information, see PHTOEH
|
ARPTDI
|
Annual Review of Pharmacology and Toxicology. (Annual Reviews, Inc., POB 10139, Palo Alto, CA
94303) V.16- 1976-
|
ARTODN
|
Archives of Toxicology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep.
Ger.) V.32- 1974-
|
ARZNAD
|
Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960
Aulendorf, Fed. Rep. Ger.) V.1- 1951-
|
AUHPAI
|
Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia)
V.1- 1971-
|
BCPCA6
|
Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY
10523) V.1- 1958-
|
BIJOAK
|
Biochemical Journal. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex
CO2 8HP, UK) V.1- 1906-
|
BJCAAI
|
British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS,
UK) V.1- 1947-
|
BJMRDK
|
Brazilian Journal of Medical and Biological Research. (Associacao Brasileira de Divulgacao
Cientifica, Faculdade de Medicina de Ribeirao Preto, USP, 141000 Ribeirao Preto, SP, Brazil)
V.14- 1981-
|
BJPCBM
|
British Journal of Pharmacology. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21
2XS, UK) V.34- 1968-
|
BMJOAE
|
British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR,
UK) V.1- 1857-
|
BRBUDU
|
Brain Research Bulletin. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY
10523) V.1- 1976-
|
CALEDQ
|
Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick,
Ireland) V.1- 1975-
|
CBINA8
|
Chemico-Biological Interactions. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick,
Ireland) V.1- 1969-
|
CEXPB9
|
Clinical and Experimental Pharmacology and Physiology. (Blackwell Scientific Publications,
(Australia) Pty Ltd., 107 Barry St., Carlton, Vic. 3053, Australia) V.1- 1974-
|
CHDDAT
|
Comptes Rendus des Seances de l'Academie des Sciences, Serie D: Sciences Naturelles. (Paris,
France) V.262-291, 1966-80. For publisher information, see CRASEV.
|
CJPPA3
|
Canadian Journal of Physiology and Pharmacology. (National Research Council of Canada,
Publication Sales and Distribution, Ottawa ON K1A OR6, Canada) V.42- 1964-
|
CLPTAT
|
Clinical Pharmacology and Therapeutics. (American Society for Clinical Pharmacology and
Therapeutics, St. Louis Mo Mosby-Year Book) V.1- 1960-
|
CMAJAX
|
Canadian Medical Association Journal. (Canadian Medical Assoc., POB 8650, Ottawa, ON K1G 0G8,
Canada) V.1- 1911-
|
CPEDAM
|
Clinical Pediatrics (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350
Virginia Ave., Hagerstown, MD 21740) V.1- 1962-
|
CRNGDP
|
Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford
OX8 1JJ, UK) V.1- 1980-
|
CRTOEC
|
Chemical Research in Toxicology. (American Chemical Soc., Distribution Office Dept. 223, POB
57/36, West End Station, Washington, DC 20037) V.1- 1988-
|
CYLPDN
|
Zhongguo Yaoli Xuebao. Acta Pharmacologica Sinica. Chinese Journal of Pharmacology. (China
International Book Trading Corp., POB 2820, Beijing, Peop. Rep. China) V.1- 1980-
|
DEPBA5
|
Developmental Psychobiology. (John Wiley & Sons, Inc., 605 Third Ave., New York, NY 10158)
V.1- 1968-
|
DIMON*
|
Disease-a Month (Chicago : Year Book Publishers) V. 24- 1978-
|
EJPHAZ
|
European Journal of Pharmacology. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam,
Netherlands) V.1- 1967-
|
EKFAE9
|
Eksperimental'naya i Klinicheskaya Farmakologiya. Experimental and Clinical Pharmacology.
(Mezhdunarodnaya Kniga, ul. B. Yakimanka, 39, 117049 Moscow, Russia) V.55- 1992-
|
ENTOX*
|
Encyclopedia of Toxicology: Reference Book, Elsevier, 2005
|
EPILAK
|
Epilepsia (New York). (Raven Press, 1185 Ave. of the Americas, New York, NY 10036) Ser.1-3:
1909-55; Ser.4: V.1- 1959-
|
ETOPFR
|
Environmental Toxicology and Pharmacology (Elsevier Science, P.O.Box 7247-7682,Philadelphia,PA
19170 -7682,USA OR Elsevier Science B.V.,P.O.Box 1270,1000 BG Amsterdam,The Netherlands) V.1-
Feb.1996-
|
EURNE*
|
European Neuropsychopharmacology (Elsevier Science, P.O.Box 7247-7682,Philadelphia,PA 19170
-7682,USA OR Elsevier Science B.V.,P.O.Box 1270,1000 BG Amsterdam,The Netherlands) V.1-
Nov.1990-
|
EXMDA4
|
International Congress Series--Excerpta Medica. (Excerpta Medica, Inc., POB 3085, Princeton,
NJ 08540) No.1- 1952-
|
FATOAO
|
Farmakologiya i Toksikologiya (Moscow). For English translation, see PHTXA6 and RPTOAN. (V/O
Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.2- 1939-
|
FCTOD7
|
Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford,
NY 10523) V.20- 1982-
|
FCTXAV
|
Food and Cosmetics Toxicology. (London, UK) V.1-19, 1963-81. For publisher information, see
FCTOD7.
|
FESTAS
|
Fertility and Sterility. (American Fertility Soc., 608 13th Ave. S, Birmingham, AL 35282)
V.1- 1950-
|
FMXXAJ
|
French Medicament Patent Document. (U.S. Patent and Trademark Office, Foreign Patents,
Washington, DC 20231) Discontinued.
|
FOMOAJ
|
Folia Morphologica (Warsaw). (Panstwowy Zaklad Wydawnictw Lekarskich, ul. Dluga 38-40, 00 238
Warsaw, Poland) V.1- 1929-
|
FTRPAE
|
Fitoterapia. (Inverni della Beffa SpA, via Ripamonti, 99, 20141 Milan, Italy) V.18- 1947-
|
GANNA2
|
Gann. Japanese Journal of Cancer Research. (Tokyo, Japan) V.1-75, 1907-84. For publisher
information, see JJCREP.
|
GEPHDP
|
General Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523)
V.6- 1975-
|
GMCRDC
|
Gann Monograph on Cancer Research. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013)
No. 11- 1971-
|
HBAMAK
|
"Abdernalden's Handbuch der Biologischen Arbeitsmethoden." (Leipzig, Ger. Dem. Rep.)
|
HETOEA
|
Human & Experimental Toxicology. (Macmillan Press Ltd., Brunel Road, Houndmills, Basingstoke,
Hampshire, RG21 2XS, UK) V.9- 1990-
|
HPTLD9
|
Hepatology (Baltimore). (Williams & Wilkins Co., Waverly Press, 428 E. Preston St.,
Baltimore, MD 21202) V.1- 1981-
|
HUTOX*
|
|
IGAYAY
|
Igaku No Ayumi. Progress in Medicine. (Ishiyaku Shuppan K.K., 1-7-10, Honkomagom, Bunkyo-ku,
Tokyo, Japan) V.1- 1946-
|
IJEBA6
|
Indian Journal of Experimental Biology. (Publications & Information Directorate, CSIR,
Hillside Rd., New Delhi 110 012, India) V.1- 1963-
|
IJMDAI
|
Israel Journal of Medical Sciences. (POB 1435, Jerusalem 91013, Israel) V.1- 1965-
|
IMEMDT
|
IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications
Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
|
JAADDB
|
Journal of the American Academy of Dermatology. (C.V. Mosby Co., 11830 Westline Industrial
Dr., St. Louis, MO 63141) 1979-
|
JACSAT
|
Journal of the American Chemical Society. (American Chemical Soc., Distribution Office Dept.
223, POB 57136, West End Stn., Washington, DC 20037) V.1- 1879-
|
JAMAAP
|
JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL
60610) V.1- 1883-
|
JAPTO*
|
Journal of Applied Toxicology (John Wiley & Sons, Ltd., Oldlands Way Bognor Regis West Sussex,
PO22 9SA England) V.1- 1981-
|
JCROD7
|
Journal of Cancer Research and Clinical Oncology. (Springer-Verlag New York, Inc., Service
Center, 44 Hartz Way, Secaucus, NJ 07094) V.93- 1979-
|
JNCIAM
|
Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher
information, see JJIND8.
|
JOPDAB
|
Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141)
V.1- 1932-
|
JPETAB
|
Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E.
Preston St., Baltimore, MD 21202) V.1- 1909/10-
|
JPHSC*
|
|
JRPMAP
|
Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969-
|
JTEHD6
|
Journal of Toxicology and Environmental Health. (Hemisphere Pub., 1025 Vermont Ave., NW,
Washington, DC 20005) V.1- 1975/76-
|
JTPAE7
|
Journal of Toxicologic Pathology. (Nihon Dokusei Byori Gakkai, editor, 3-25-8 Nishi-
shinbashi, Minato-ku, Tokyo 105, Japan) V.1- 1988
|
JTSCDR
|
Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor,
Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976-
|
LANCAO
|
Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823-
|
LIFSAK
|
Life Sciences. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1-8,
1962-69; V.14- 1974-
|
MUREAV
|
Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1-
1964-
|
MUTAEX
|
Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ,
UK) V.1- 1986-
|
NEJMAG
|
New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA
02115) V.198- 1928-
|
NRTXDN
|
Neurotoxicology. (Intox Press, Inc., POB 34075, Little Rock, AR 72203) V.1- 1979-
|
NSAPCC
|
Naunyn-Schmiedeberg's Archives of Pharmacology. (Springer Verlag, Heidelberger, Pl. 3, D-1000
Berlin 33, Fed. Rep. Ger.) V.272- 1972-
|
NTIS**
|
National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse
for Scientific & Technical Information.
|
NTPTR*
|
National Toxicology Program Technical Report Series. (Research Triangle Park, NC 27709)
No.206-
|
NUPOBT
|
Neuropatologia Polska. (Ars-Polona, POB 1001, 00-068 Warsaw 1, Poland) V.1- 1963-
|
PAREAQ
|
Pharmacological Reviews. (Williams & Wilkins, 428 E. Preston St., Baltimore, MD 21202) V.1-
1949-
|
PCJOAU
|
Pharmaceutical Chemistry Journal (English Translation). Translation of KHFZAN. (Plenum Pub.
Corp., 233 Spring St., New York, NY 10013) No.1- 1967-
|
PEDIAU
|
Pediatrics. (American Academy of Pediatrics, P.O. Box 1034, Evanston, IL 60204) V.1- 1948-
|
PHARAT
|
Pharmazie. (VEB Verlag Volk und Gesundheit, Neue Gruenstr. 18, Berlin DDR-1020, Ger. Dem.
Rep.) V.1- 1946-
|
PHREA7
|
Physiological Reviews. (American Physiological Soc., 9650 Rockville Pike, Bethesda, MD 20814)
V.1- 1921-
|
PHTOEH
|
Pharmacology and Toxicology (Copenhagen). (Munksgaard International Pub., POB 2148, DK-1016
Copenhagen K, Denmark) V.60- 1987-
|
PLMJAP
|
Pahlavi Medical Journal. (Shiraz, Iran) V.1-9, 1970-78.
|
PMRSDJ
|
Progress in Mutation Research. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New
York, NY 10017) V.1- 1981-
|
PPHAD4
|
Pediatric Pharmacology. (New York, NY) V.1-5, 1980-86. For publisher information, see
DPTHDL.
|
PRSMA4
|
Proceedings of the Royal Society of Medicine. (New York, NY) V.1-70, 1907-77. For publisher
information, see JRSMD9.
|
PSCHDL
|
Psychopharmacology (Berlin). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way,
Secaucus, NJ 07094) V.47- 1976-
|
PSEBAA
|
Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E.
First St., Duluth, MN 55802) V.1- 1903/04-
|
REPTED
|
Reproductive Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY
10523) V.1- 1987-
|
RUXXAF
|
Russian Federation Patent Document. (Gosudarstvennyi Komitet SSSR po Delam Izobretenii i
Otkrytii, Malyi Tcherkasski pereulok 2/6, Moscow, Russia).
|
SCIEAS
|
Science. (American Assoc. for the Advancement of Science, 1333 H St., NW, Washington, DC
20005) V.1- 1895-
|
SEIJBO
|
Senten Ijo. Congenital Anomalies. (Nippon Senten Ijo Gakkai, c/o Kinki Daigaku Igakubu
Kaibagaku Kyoshitsu, 380 Nishiyama, Sayama-cho, Mirami-Kawachi-gun, Osaka-fu, Japan) V.1-26,
1960-86. For publisher information, see CGANE7.
|
SMWOAS
|
Schweizerische Medizinische Wochenschrift. (Schwabe & Co., Steintorst 13, 4010 Basel,
Switzerland) V.50- 1920-
|
SOGEBZ
|
Soviet Genetics. English translation of GNKAA5. (Plenum Pub. Corp., 233 Spring St., New
York, NY 10013) V.2- 1966-
|
TJADAB
|
Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E.
11th St., New York, NY 10003) V.1- 1968-
|
TJEMAO
|
Tohoku Journal of Experimental Medicine. (Maruzen Co. Ltd., Export Dept., P.O. Box 5050,
Tokyo Int., 100-31 Tokyo, Japan) V.1- 1920-
|
TOLED5
|
Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands)
V.1- 1977-
|
TOPADD
|
Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical
Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978-
|
TOSCF2
|
Toxicological Sciences (Oxford University Press, 6277 Sea Harbor Drive, Orlando, FL 32887 )
V. 41, Jan. 1998-
|
TOVEFN
|
Toksikologicheskii Vestnik. (18-20 Vadkovskii per. Moscow, 101479, Russia) History Unknown
|
TOXID9
|
Toxicologist. (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1-
1981-
|
TPHSDY
|
Trends in Pharmacological Sciences. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New
York, NY 10017) V.1- 1979-
|
TXAPA9
|
Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802)
V.1- 1959-
|
TXCYAC
|
Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-
|
VOONC*
|
Voprosi oncologii (Questions of oncology. Journal of Petrov's Institute of Oncology, B.
Zelenina str, 43a, Spb 197110, Russia) V.1- 1955-
|
YAKUD5
|
Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho,
Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959-
|
| |